DelveInsight’s, “Advanced Merkel cell carcinoma Pipeline Insight 2024″ report provides comprehensive insights about 20+ Advanced Merkel Cell Carcinoma Companies and 20+ pipeline drugs in the Advanced Merkel cell carcinoma pipeline landscape. It covers the Advanced Merkel Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Merkel Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Advanced Merkel Cell Carcinoma Pipeline Report

• DelveInsight’s Advanced Merkel Cell Carcinoma pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Advanced Merkel Cell Carcinoma treatment.
• The leading companies working in the Advanced Merkel Cell Carcinoma market include Xencor Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis Inc., Checkpoint Therapeutics, Inc., and others.
• Promising Advanced Merkel Cell Carcinoma Pipeline Therapies in the various stages of development include Pembrolizumab (MK-3475), Avelumab, Cemiplimab-Rwlc, FF-10850 Topotecan Liposome Injection, IFx-Hu2.0, Vidutolimod, Cemiplimab, INCB099318, SO-C101, CK-301 (cosibelimab), and others.
• December 2023: Regeneron Pharmaceuticals announced a study of Phase 2 clinical trials for vidutolimod and cemiplimab. The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have an end of treatment visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.
• December 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Pembrolizumab (MK-3475). This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial is to assess the objective response rate, as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, following administration of pembrolizumab.
• On August 2023, H. Lee Moffitt Cancer Center and Research Institute announced a study of Phase 1 Clinical Trials for Cemiplimab-Rwlc. The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating (1) Merkel Cell Carcinoma or (2) Cutaneous Squamous Cell Carcinoma (CSCC).
• On July 2023, 4SC AG announced a study of Phase 2 Clinical Trials for Domatinostat in Combination with Avelumab. This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with advanced unresectable and/or metastatic Merkel Cell Carcinoma that have progressed on a previous therapy with an anti-PD-(L)1 antibody.
• On June 2023, Memorial Sloan Kettering Cancer Center announced a study of Phase 2 Clinical Trials for Avelumab. This study will test the use of comprehensive ablative radiation therapy (CART), with the immunotherapy drug avelumab, in people with Merkel cell carcinoma (MCC) that has progressed after treatment and cannot be removed with surgery. The study researchers want to find out if CART works well when combined with avelumab.
• On February 2023, Merck Sharp & Dohme LLC announced a study of Phase 3 Clinical Trials for Pembrolizumab (MK-3475). This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial is to assess the objective response rate, as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, following administration of pembrolizumab.

 

Request a sample and discover the recent advances in Advanced Merkel Cell Carcinoma Treatment Drugs @ Advanced Merkel Cell Carcinoma Infection Pipeline Report

 

The Advanced Merkel Cell Carcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Merkel Cell Carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Merkel Cell Carcinoma clinical trial landscape.

 

Advanced Merkel Cell Carcinoma Overview

Advanced Merkel cell carcinoma (MCC) is a very aggressive, rare neuroendocrine tumor of the skin with a high frequency of locoregional recurrence and metastasis, and a high mortality rate. Surgical resection, sentinel lymph node biopsy, and radiotherapy represent the gold standard of treatment in patients with localized disease, while chemotherapy has a significant role in the treatment of advanced disease.

 

Find out more about Advanced Merkel Cell Carcinoma Treatment Drugs @ Drugs for Advanced Merkel Cell Carcinoma Treatment

 

Advanced Merkel Cell Carcinoma Emerging Drugs Profile

• Tidutamab: Xencor, Inc.
• Cabozantinib: Exelixis

 

Advanced Merkel Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Advanced Merkel cell carcinoma. The Advanced Merkel Cell Carcinoma companies which have their Advanced Merkel cell carcinoma drug candidates in the most advanced stage, i.e. phase II include, Exelixis.

 

Learn more about the emerging Advanced Merkel Cell Carcinoma Pipeline Therapies @ Advanced Merkel Cell Carcinoma Clinical Trials Assessment

 

Scope of the Advanced Merkel Cell Carcinoma Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Advanced Merkel Cell Carcinoma Companies- Xencor Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis Inc., Checkpoint Therapeutics, Inc., and others.
• Advanced Merkel Cell Carcinoma Pipeline Therapies- Pembrolizumab (MK-3475), Avelumab, Cemiplimab-Rwlc, FF-10850 Topotecan Liposome Injection, IFx-Hu2.0, Vidutolimod, Cemiplimab, INCB099318, SO-C101, CK-301 (cosibelimab), and others.

 

Dive deep into rich insights for new drugs for Advanced Merkel Cell Carcinoma treatment, Visit @ Advanced Merkel Cell Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Advanced Merkel cell carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced Merkel cell carcinoma – DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase II)
8. Cabozantinib: Exelixis
9. Drug profiles in the detailed report…..
10. Early Stage Products (Phase I)
11. IFx-Hu2.0: Morphogenesis
12. Drug profiles in the detailed report…..
13. Inactive Products
14. Advanced Merkel cell carcinoma Key Companies
15. Advanced Merkel cell carcinoma Key Products
16. Advanced Merkel cell carcinoma- Unmet Needs
17. Advanced Merkel cell carcinoma- Market Drivers and Barriers
18. Advanced Merkel cell carcinoma- Future Perspectives and Conclusion
19. Advanced Merkel cell carcinoma Analyst Views
20. Advanced Merkel cell carcinoma Key Companies
21. Appendix

 

For further information on the Advanced Merkel Cell Carcinoma pipeline therapeutics, reach out to Advanced Merkel Cell Carcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services